Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory by Fagan, Anne M et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2018
Cerebrospinal fluid biomarkers predict
frontotemporal dementia trajectory
Anne M. Fagan
Washington University School of Medicine in St. Louis
Gina Jerome
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Fagan, Anne M.; Jerome, Gina; and et al, ,"Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory." Annals of
Clinical and Translational Neurology.5,10. 1250-1263. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7231
RESEARCH ARTICLE
Cerebrospinal fluid biomarkers predict frontotemporal
dementia trajectory
Peter A. Ljubenkov1, Adam M. Staffaroni1, Julio C. Rojas1, Isabel E. Allen2, Ping Wang1,
Hilary Heuer1, Anna Karydas1, John Kornak2, Yann Cobigo1, William W. Seeley1,
Lea T. Grinberg1, Salvatore Spina1, Anne M. Fagan3, Gina Jerome3, David Knopman4, Brad F. Boeve4,
Bradford C. Dickerson5, Joel Kramer1, Bruce Miller1, Adam L. Boxer1 & Howard J. Rosen1
1Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, California
2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California
3Department of Neurology, Washington University, St. Louis, Missouri
4Department of Neurology, Mayo Clinic, Rochester, Minnesota
5Frontotemporal Dementia Unit, Department of Neurology, Massachusetts Alzheimer’s Disease Research Center, Harvard Medical School, Boston,
Boston, Massachusetts
Correspondence
Peter A. Ljubenkov, University of California,
San Francisco 675 Nelson Rising Lane, Suite
190, San Francisco, CA 94158.
Tel: 415.502.7562; Fax: 415.476.2921;
E-mail: Peter.Ljubenkov@ucsf.edu
Funding Information
This study was made possible through
funding by the National Institute of Health
(NIH), National Institute on Aging (NIA) and
was supported by the following grants: K24
AG045333-01, P01 AG019724-09, P50
AG23501 R01 AG032306, U54 NS092089.
Received: 26 July 2018; Accepted: 10 August
2018
Annals of Clinical and Translational
Neurology 2018; 5(10): 1250–1263
doi: 10.1002/acn3.643
Abstract
Objective: The prognostic value of cerebrospinal fluid neurofilament light
chain, total tau, phosphorylated tau181, and amyloid beta1-42 was examined in
frontotemporal dementia subtypes. Methods: We compared baseline biomarkers
between 49 controls, 40 patients with behavioral variant frontotemporal demen-
tia, 24 with semantic variant primary progressive aphasia, and 26 with nonflu-
ent variant primary progressive aphasia. Linear mixed effect models were used
to assess the value of baseline biomarkers in predicting clinical and radiographic
change in patient cohorts over multiple yearly follow up visits. Results: Neuro-
filament light chain concentrations were lowest in controls. Elevated baseline
neurofilament light chain predicted faster worsening in clinical severity, fron-
totemporal volume and frontotemporal fractional anisotropy in patients with
behavioral variant frontotemporal dementia and nonfluent variant primary pro-
gressive aphasia. High total tau similarly predicted faster progression in nonflu-
ent variant primary progressive aphasia. In behavioral variant frontotemporal
dementia, higher phosphorylated tau181 predicted faster clinical progression
whereas lower amyloid beta1-42 predicted faster volumetric and fractional aniso-
tropy reduction. Neurofilament light chain and phosphorylated tau181 were of
greater predictive value in patients with tau pathology as compared to TDP-43
pathology. Baseline neurofilament light chain correlated with baseline clinical
severity and frontotemporal volume in behavioral variant frontotemporal
dementia. Baseline total tau correlated with baseline clinical severity in semantic
variant primary progressive aphasia. Interpretation: High cerebrospinal fluid
neurofilament light chain predicts more aggressive disease in behavioral variant
frontotemporal dementia and nonfluent variant primary progressive aphasia.
Total tau, phosphorylated tau181, and amyloid beta1-42 also predict some mea-
sures of disease aggressiveness in frontotemporal dementia.
Introduction
Frontotemporal dementia (FTD) is a heterogeneous group
of degenerative clinical syndromes, including behavioral
variant frontotemporal dementia (bvFTD), nonfluent vari-
ant primary progressive aphasia (nfvPPA), and semantic
variant primary progressive aphasia (svPPA). Patients with
FTD show diverse patterns of clinical progression, radio-
graphic change, and underlying frontotemporal lobar
degeneration (FTLD) pathologies, including FTLD with
tau immunoreactive inclusions (FTLD-tau) and pathology
with transactive response DNA-binding protein 43 kDa
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inclusions (FTLD-TDP).1 Future therapeutic trials in FTD
must grapple with this heterogeneity in order to establish
drug efficacy. Cerebrospinal fluid (CSF) biomarkers may
provide a relatively uniform measure of disease biology,
reflecting disease severity and drug target engagement, and
thus provide evidence of drug efficacy when followed lon-
gitudinally.2 CSF biomarkers may also be associated with
overall aggressiveness of disease, which may help to select
patients predicted to show similar progression trajectories
in clinical trials.
CSF amyloid beta1-42 (Ab1-42) and tau distinguish
FTLD from Alzheimer’s disease (AD),3 but they are not
consistently abnormal in FTD2,4,5 and are largely unex-
plored as predictors of changes in FTD disease severity.
Recent studies in FTD suggest that serum and CSF neuro-
filament-light chain (NfL), an intermediate cytoskeletal
element that elevates upon neuronal injury,6 is a reliable
marker of disease onset,7 clinical severity,7–9 disease prog-
nosis,7,10 and brain atrophy rates.7,9 Few studies, however,
have addressed the relative value of NfL in prediction of
disease progression in different FTD cohorts. Addition-
ally, there is limited data comparing the predictive value
of NfL to other CSF biomarkers, such as Ab1-42, total tau
(t-tau) and phosphorylated tau181 (p-tau). Additionally,
despite the importance of tau and NfL in determining
axon structure and function, there are few data on how
well these CSF biomarkers predict progression of diffu-
sion tensor imaging (DTI) measures of axonal integrity.
In this study, we investigated the value of CSF NfL,
t-tau, p-tau and Ab1-42 in predicting disease progression
within and between each of the three canonical FTD
variants, as well as in neuropathologically or genetically
confirmed FTLD-tau and FTLD-TDP. Since these data
have potential implications for clinical trial design, we
compared the ability of CSF biomarkers to predict change
to a variety of clinical and radiographic disease progres-
sion measures, including neuropsychological testing, volu-
metric MRI, and DTI measures of white matter
microstructure.
Methods
Participants
Baseline CSF biomarker concentrations, longitudinal clini-
cal data, and longitudinal imaging data were studied in 90
patients with frontotemporal dementia (40 bvFTD, 24
svPPA, 26 nfvPPA) (Table 1). CSF data from 49 healthy
age-matched controls was also included for comparison.
Data were collected from three medical centers (University
of California, San Francisco [UCSF], Massachusetts Gen-
eral Hospital [MGH], Mayo Clinic, Rochester [MCR]) via
the Frontotemporal Lobar Degeneration Neuroimaging
Initiative (FTLDNI) and the UCSF program project grant
in frontotemporal dementia. The Institutional Review
Board (IRB) of each contributing site previously approved
study protocols. Patients were diagnosed by a multidisci-
plinary consensus panel using current (at the time of study
enrollment) consensus diagnostic criteria for bvFTD,11,12
svPPA,13 and nfvPPA.13 Baseline CSF samples were
matched with baseline clinical and radiographic data
within 90 days of sample collection. The majority (84%) of
cases also had one or more additional clinical data and
radiographic data points after their baseline visit (Table 1).
The average follow-up interval was between 9 and
10 months. Intervals were not regular within or between
patients. There was not a statistically significant difference
in follow-up interval lengths between individual FTD
cohorts (Kruskal Wallis P < 0.05). In order to account for
the irregularity of follow-up intervals, time was used as a
continuous variable (years from baseline CSF value) in all
linear mixed-effect models.
CSF Assessment
NfL, t-tau, p-tau, and Ab1-42 concentrations were mea-
sured from frozen CSF samples collected between May
2009 and May 2015. CSF samples were collected via lum-
bar puncture into sterile polypropylene tubes, using a
previously described protocol.8 Within 30 min of collec-
tion, CSF samples were centrifuged at 2000g at room
temperature (20–25°C) for 5 min, aliquoted into 500 lL
cryovials and stored at 80°C, until further analysis. All
fluid biomarkers were measured from baseline CSF, previ-
ously collected during or prior to earliest clinical and MR
imaging assessment. NfL concentrations were also mea-
sured in follow-up CSF samples (within 2 years after
baseline) in 27 patients with FTD (14 with bvFTD, 8 with
nfvPPA, and 5 with svPPA) to provide longitudinal data
on NfL change. Longitudinal data was not collected for
t-tau, p-tau, or Ab1-42. All biomarkers were measured in
duplicate (twice concurrently) to ensure coefficients of
variance<25%, and the average concentration was used in
our analyses. Ab1-42, total tau (t-tau), and hyperphospho-
rylated tau (p-tau) concentrations were measured with
the INNO-BIA AlzBio3 platform (Fujirebio, Belgium).
Neurofilament light-chain (NfL) levels were quantified
using the Uman Diagnostics enzyme-linked immunosor-
bent assay kit (Umea, Sweden). All NfL samples were per-
formed using a 1:4 dilution as specified in the Uman
Diagnostic kit instructions, and were otherwise performed
using previously described kit methods.8 NfL concentra-
tions were first assessed on 7/26/2012 and 4/24/2013 by a
clinical research organization, Bristol-Myers Squibb
(BMS), in an initial cohort of 27 patients (14 with
bvFTD, 8 with nfvPPA, and 5 with svPPA). Data obtained
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from BMS (along with contemporaneous clinical and vol-
umetric data) were previously used in separately pub-
lished cross-sectional analyses.8 In order to expand our
sample size, NfL concentrations in a larger cohort of
patients (26 with bvFTD, 22 with nfvPPA, 19 with svPPA,
49 controls) were measured on 7/15/2015 and 1/12/16 by
the Fagan lab, Washington University, St. Louis. The
Fagan lab also performed CSF Ab1-42, t-tau and p-tau
assays for all 139 subjects in our study on 7/15/2015 and
1/12/16. The laboratory site of biomarker assessment was
included as a covariate in all statistical analyses of NfL
levels. Among patients with FTD, there was no difference
between NfL concentrations calculated by the Fagan lab
and BMS (P-value = 0.6).
Classification of patients according to
causative proteinopathy
To examine whether the predictive value of NfL is dif-
ferent for FTLD-tau vs. FTLD-TDP, we assigned cases
into groups based on the best available data. Diagnostic
information from postmortem brain examination, using
previously described methods,14 was used if available. If
autopsy data was not available (whether it was not
obtained or the patient was still alive), but an FTD-
causing mutation was identified, gene status was used
to identify the putative FTLD major molecular class. If
neither autopsy nor mutation data were available, we
assigned some patients to a proteinopathy group if they
developed either a motor neuron disease secondary
clinical phenotype (strongly associated with FTLD-TDP)
or a Steele-Richardson progressive supranuclear palsy
(PSP) secondary clinical phenotype15 (strongly associ-
ated with FTLD-tau). Using this enrichment approach,
we were able to assign a likely underlying pathology in
35 cases (20 with FTLD-tau and 15 with FTLD-TDP)
(Table 1). Autopsy data was available in 12 cases with
bvFTD, 11 cases with nfvPPA and one case with
svPPA. Within the bvFTD group, six patients had
FTLD-tau pathology at autopsy (two with Pick’s
Table 1. Patient demographics and CSF biomarker levels.
All FTD bvFTD nfvPPA svPPA Controls
Total cases with CSF, n 90 40 26 24 49
Cases with clinical data, n
[average number of time points]
87 40 [2.6] 26 [2.7] 24 [2.9]
Cases with volumetric MRI, n
[average number of time points]
81 36 [2.6] 22 [2.7] 23 [2.7]
Cases with DTI, n
[average number of time points]
80 36 [2.4] 24 [2.3] 20 [2.9]
Female/Male 36/54 15/25 11/15 13/11 22/27
Presumed FTLD-tau/FTLD-TDP 20/15 8/13 12/1 0/1
Cases with t-tau/Ab1-42 > 0.52 5 4 0 1 0
Mean age, years (SD) 63.3 (7.5) 61.0 (6.2)1 68.0 (8.0)1 62.1 (6.9) 64 (7.8)
Mean disease duration, years (SD) 5.2 (3.5) 5.3 (3.4) 4.7 (4.4) 5.5 (2.8)
Mean FTLD-CDR SB (SD) 7.19 (3.77)2 9.42 (3.55)2 4.69 (2.90)2 6.46 (2.94)2
Mean frontotemporal volume,
mm3 (SD)
1.77 9 105
(0.25x105)
1.72 9 105
(0.31 9 105)
1.78 9 105
(0.22 9 105)
1.84 9 105
(0.16 9 105)
Frontotemporal FA (SD) 0.394 (0.026) 0.3903 (0.033) 0.399 (0.022) 0.395 (0.020)
Baseline CSF biomarker levels
NfL pg/mL (SD) 5.7 9 103
(4.0 9 103)3
5.61 9 103
(4.8 9 103)3
4.7 9 103
(2.1 9 103)3
6.9 9 103
(3.7 9 103)3
1.3 x103
(6.1 9 103)3
Total Tau pg/mL (SD) 82.1 (37.1) 80.1 (41.1) 80.1 (26.8) 87.6 (40.4) 72.0 (26.3)
p-ta pg/mL (SD) 22.9 (9.7) 21.7 (9.8) 23.3 (10.4) 24.4 (8.8) 25.3 (8.1)
Ab1-42 pg/mL (SD) 410 (160) 390 (170) 430 (140) 440 (180) 480 (170)
Total Tau/Ab1-42 (SD) 0.24 (0.18) 0.26 (0.23) 0.21 (0.11) 0.22 (0.13) 0.17 (0.10)
p-tau/t-tau (SD) 0.33 (0.13) 0.31 (0.14)4 0.29 (0.11)4 0.31 (0.13) 0.37 (0.12)
Ab1-42, amyloid beta1-42; bvFTD, behavioral variant frontotemporal dementia; CSF, cerebrospinal fluid; FA, fractional anisotropy; NfL, neurofila-
ment light chain; nfvPPA, nonfluent variant primary progressive aphasia, p-tau, phosphorylated tau181; SD, standard deviation; svPPA, semantic
variant primary progressive aphasia; t-tau, total tau.
1Indicates a statistically significant difference in age between groups (P = 0.001) between bvFTD and nfvPPA.
2Indicates a statistically significant difference in CDR-FTLD SB between groups (P = 0.0001) with svPPA higher than nfvPPA and bvFTD being
higher than both PPA variants in post hoc pairwise comparisons (P < 0.05).
3Indicates that values in controls are statistically significantly lower in pairwise comparisons with all 3 symptomatic cohorts (P < 0.05).
4Indicates that p-tau/t-tau ratio is lower in bvFTD and nfvPPA than in controls (P < 0.05).
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disease, one with agyrophilc grain disease, one with
PSP, and two with corticobasal degeneration), and six
patients showed FTLD-TDP (one with sporadic FTLD-
TDP type A, one with FTLD-TDP Type A secondary to
GRN mutation, three with sporadic FTLD-TDP Type B
and motor neuron disease, and one with unclassifiable
FTLD-TDP secondary to C9ORF72 expansion). An
additional two patients with bvFTD were classified as
tauopathy based on MAPT mutations and six additional
living patients had mutations associated with FTLD-
TDP (five with C9ORF72 expansions and one with a
GRN mutation). Two patients with bvFTD due to
C9ORF72 expansion also developed motor neuron dis-
ease later in their course. One additional patient with
bvFTD and motor neuron disease was presumed to
have FTLD-TDP pathology. Within the nfvPPA cohort,
10 cases had FTLD-tau pathology at autopsy (two with
Pick’s disease, one with an unclassifiable four repeat
tauopathy, six with corticobasal degeneration, and one
with PSP pathology), and one had FTLD-TDP Type B
pathology with motor neuron disease. Two living
patients with nfvPPA were presumed to have FTLD-tau
pathology because of accompanying clinical features suf-
ficient to also meet clinical research criteria for the
Steele-Richardson PSP syndrome.15 One patient with
svPPA had autopsy data that confirmed the presence of
FTLD-TDP type B pathology. A total tau/Ab1-42 ratio
of 0.52 was used to define CSF criteria for AD.16 Only
five cases met CSF criteria for AD (four cases with
bvFTD, one case with svPPA, and no cases with
nfvPPA).
Clinical assessment
General functional severity was assessed using the FTLD
modified clinical dementia rating scale, sum of boxes
score (CDR-FTLD SB), and established measure of clini-
cal decline in FTD.17 Patients were also assessed using the
Functional Assessment Questionnaire (FAQ),18 the Clini-
cian’s Global Impression Scale (CGI),19 the Schwab and
England Activities of Daily Living scale (SEADL),20 the
Neuropsychiatric Inventory (NPI),21 the Mini-Mental
State Examination (MMSE),22 the California Verbal
Learning Test, Second Edition-Short Form (CVLT),23
digit span (backward and forward),24 a modified Trail-
making task,25 the Stroop color naming and inhibition
tasks,26 phonemic fluency (D-words/minute),25 semantic
fluency (animals/minute),27 the 15-item Boston Naming
Test (BNT),28 the short version of the Peabody Pic-
ture Vocabulary Test-Revised (PPVT),29 the Pyramids
and Palm Trees test of sematic access,30 and a copy of the
Modified Rey Benson Figure.25
Structural MRI analyses
We obtained volumetric magnetic resonance images at
UCSF and MGH, using a 3T Siemens Tim Trio system
equipped with a 12-channel head coil. Images obtained at
MCR were acquired on a 3T GE MRI scanner equipped
with an 8-channel head coil. T1 acquisition and process-
ing were performed under previously described meth-
ods.31 Brain volumes were calculated for specific brain
regions at each time point by transforming a standard
parcellation atlas32 into ICBM space and summing all
modulated gray matter within each specified parcellated
region. Lobar composites were used to reduce the number
of regions of interest (ROI) in our analysis. Right and left
frontal lobe composites were created using the sum of
volumes within the following regions: anterior cingulate
(caudal and rostral), frontal pole, insula, lateral orbito-
frontal cortex, medial orbitofrontal cortex, middle frontal
gyrus, pars opercularis, pars orbitalis, pars triangularis,
superior frontal gyrus, and precentral gyrus. We created
right and left temporal lobe composites using the sum of
volumes in the following regions: banks of the superior
temporal sulcus, entorhinal cortex, fusiform gyrus, middle
temporal gyrus, parahippocampal cortex, superior tempo-
ral gyrus, temporal pole, and transverse temporal gyrus.
We then summed volumes in the resulting right frontal,
left frontal, right temporal and left temporal lobe com-
posites to produce total frontotemporal composite ROI.
We created a global frontotemporal volumetric ROI by
summing the frontal and temporal composite ROIs.
DTI analyses
DTI acquisition and processing were performed using
previously described methods using scans from UCSF.33
DTI ROIs were obtained, using the ICVM-DTI-81 white
matter labels and tract atlas.34 We again created compos-
ite ROIs. The right and left frontal composite ROIs repre-
sented the average fractional anisotropy (FA) of tracts
conveying fibers that entered and exited the frontal lobes,
including the superior longitudinal fasciculus and cingu-
lum bundle. The right and left temporal composite ROIs
represented the average FA from the fornix, inferior lon-
gitudinal fasciculus, sagittal stratum, and hippocampal
portion of the cingulum. FA within the genu of the cor-
pus callosum, the right uncinate fasciculus, and left unci-
nate fasciculus were also analyzed but not included in
lobar composites. We created a global frontotemporal
DTI ROI by averaging FA in the genu of the corpus callo-
sum, the bilateral uncinated fasciculus, and the right and
left constituent ROIs previously used to create our frontal
and temporal composite ROI.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1253
P. A. Ljubenkov et al. CSF Biomarkers Predict FTD Trajectory
Statistics
We performed basic descriptive statistics for demo-
graphic data and CSF protein levels. The normality of
continuous cross-sectional data was assessed via the
skewness kurtosis test.35 Non-normally distributed values
(CDR-FTLD SB, NfL, t-tau, Ab1-42, t-tau/Ab1-42 ratio)
were compared using nonparametric methods, including
the Kruskal–Wallis test followed by post hoc Wilcoxon
pairwise rank sum testing. Normally distributed mea-
sures (p-tau, p-tau/t-tau, age) were compared between
cohorts with Analysis of Variance (ANOVA), followed
by a post hoc pairwise Tukey test. A Bonferroni correc-
tion was used to correct for multiple pairwise compar-
isons across five differing CSF measures (a = 0.05/
5 = 0.01). In light of previously published studies,36,37
we also used a receiver operating characteristic (ROC)
analysis to investigate the utility of p-tau/t-tau ration in
detecting FTLD-TDP pathology en vivo.
We hypothesized that CSF protein biomarkers (NfL, t-
tau, p-tau, Ab1-42) would predict change in three primary
selected measures of disease severity: the CDR-FTLD SB,
frontotemporal volume, and frontotemporal fractional
anisotropy (FA). In order to compare the effect sizes
between CSF markers, the mean and standard deviations
(SD) (Table 1) for our entire FTD cohort (n = 90) were
used to create Z-score values for NfL, total tau, p-tau,
and Ab1-42 for each patient (thus allowing effect sizes to
be conveyed in terms of standard deviation from the
mean). We subsequently used these Z-scores as continu-
ous variables for cross-sectional regression models and
linear mixed effect models (LME) performed in this
study.
In order to leverage data from cases with three or
more data points, we used LME models to estimate
interactions between biomarkers and time (both contin-
uous variables) in determining disease measures. Bio-
marker level, age, and sex were included as fixed effects.
Figure 1. CSF biomarkers by clinical cohort. A, CSF NfL, B, t-tau, C, p-tau, D, Ab1-42, E, t-tau/Ab1-42 ratio and F, p-tau/t-tau ratio respectively.
Circles represent individual participants in the study. Whiskers represent the highest and lowest adjacent values ( 1.5 x interquartile range) with
a median line in between. All three FTD cohorts differed from controls in pairwise comparisons (P < 0.0001). Ab1-42, amyloid beta1-42; bvFTD,
behavioral variant frontotemporal dementia; CSF, cerebrospinal fluid; NFL, neurofilament light chain; nfvPPA, nonfluent variant primary
progressive aphasia; p-tau, phosphorylated tau181; svPPA, semantic variant primary progressive aphasia; t-tau, total tau.
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The lab of NfL measurement and total intracranial vol-
ume (TIV) were also included as fixed effects in models
containing NfL and volumetric data, respectively. We mod-
eled time as a fixed effect and allowed each patient to have
a random intercept to account for differing baseline sever-
ity. In order to assess whether the value of biomarkers dif-
fered by clinical cohort, we first tested three-way
interactions between biomarkers, diagnosis (a fixed effect),
and time. Given the apparent interaction between diagnosis
and biomarker predictors, we elected to assess each canoni-
cal FTD variant separately in our two-way LME models.
We selected a conservative approach to correct for multiple
comparisons to focus on easily reproducible findings for
future clinical trial use. A Bonferroni correction (a = 0.05/
3 = 0.017) was applied to analyses of our three primary
measures. As a sensitivity analysis, all statistically significant
findings were reanalyzed after excluding cases with possible
contributory non-FTLD co-pathology, including three
patients with bvFTD and possible AD biomarkers, six cases
with bvFTD and evidence of motor neuron disease, one
case with nfvPPA and motor neuron disease, and one
patient with svPPA and positive AD biomarkers. In order
to provide a clinically useful presentation of data, we calcu-
lated annual clinical change (using LME models with no
interaction) above and below the median CSF concentra-
tion for every biomarker that predicted CDR-FTLD. Follow
up post hoc analysis (using previously discussed two-way
interaction LME models) then assessed predictors of
change in 30 additional clinical and radiographic measures
of disease decline (Tables S1–S3). A Bonferroni correction
was applied (a = 0.05/30 = 0.0017) to results for our 30
follow up measures of disease severity. Finally, we modeled
interactions between underlying pathology (a fixed effect),
biomarkers, and time in determining disease severity in a
cohort of cases with bvFTD or nfvPPA phenotypes. The
magnitude of the estimated three-way interaction coeffi-
cient was used to assess the relative predictive value of
biomarkers in FTLD-tau relative to FTLD-TDP. After each
LME model analysis a postestimation of standardized resid-
uals was performed to ensure the normality of their distri-
bution. All statistically significant findings were rerun as a
sensitivity analysis with patients with motor neuron disease
(severe patients with bvFTD, one with nfvPPA) and/or CSF
criteria for AD (four cases with bvFTD, one case with
svPPA) excluded from analysis.
Linear regression was used to estimate and assess the
statistical significance of relationships between CSF pro-
tein concentrations and each of our three primary mea-
sures of interest within each of the three FTD clinical
cohorts of interest. Baseline CDR-FTLD was not normally
distributed in nfvPPA, so a log transformed value was
used in our nfvPPA regression models. In cases with lon-
gitudinal NfL data, linear regression was also used to
estimate the change in CSF NfL over time. We utilized
NfL change (NfL value 2 – NfL value 1) as the dependent
variable and duration between time points (in years) as
an independent variable. Longitudinal t-tau, p-tau, and
Ab1-42 values were not available for analysis. Age and sex
were included as covariates in all regression models. The
lab of measurement and total intracranial volume (TIV)
were also included as covariates in regression models con-
taining NfL and volumetric data, respectively.
Results
Patient demographics
Basic demographic information is presented in Table 1.
Patients with nfvPPA were older than patients with
bvFTD, though none of the FTD groups differed from
age-matched controls. Patients with bvFTD had a higher
CDR-FTLD SB score than patients with svPPA or patients
with nfvPPA. Additionally, patients with svPPA had a
higher FTLD-CDR SB than patients with nfvPPA. Patients
with svPPA tended to have higher CSF NfL levels than
other FTD variants, but this difference was not statisti-
cally significant. Controls had lower CSF NfL than all
three disease variants in all pairwise comparisons
(Fig. 1A). CSF p-tau/t-tau ratio was lower in patients
with bvFTD and nfvPPA compared to healthy controls
(Fig. 1F). Additionally, patients with presumed FTLD-
TDP pathology tended to have a lower CSF p-tau/t-tau
ratio than patients with presumed FTLD-tau (P = 0.02)
(Table 2). A p-tau/t-tau ratio less than or equal to 0.29
gave an AUC of 0.7 (SD 0.47, P = 0.003), a specificity of
70% specific and sensitivity of 65.3% in detecting FTLD-
TDP from our cohort with discernable pathology
(Table S1). CSF t-tau/Ab1-42 ratio tended to be lower in
controls compared to patients with bvFTD, svPPA, and
nfvPPA, but these findings were not significant after
adjusting for multiple comparisons. There was no differ-
ence in CSF t-tau, p-tau, or Ab1-42 concentrations
between any of our clinical (controls, bvFTD, nfvPPA or
svPPA) or pathologic cohorts.
CSF biomarkers correlate with clinical
severity and brain volume
In patients with bvFTD, high baseline CSF NfL was linearly
related to high baseline CDR-FTLD SB (1.36 CDR units/SD
NfL, 95% CI [0.41, 2.31], P = 0.006, R2=0.23) and low
baseline frontotemporal volume (8.4 9 103 mm3/SD
NfL, 95% CI [15 9 103, 2.0 9 103], P = 0.012,
R2 = 0.65). In patients with svPPA, high baseline t-tau
(1.44 units/SD NfL, 95% CI [0.29, 2.59], P = 0.016,
R2=0.26) was linearly related to CDR-FTLD SB.
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Baseline NfL and p-tau predict longitudinal
change in bvFTD
Higher baseline levels of CSF NfL, total tau, and p-tau
predicted a faster rate of CDR-FTLD SB worsening in
patients with bvFTD (Table 3, Fig. 2A–C). However, after
excluding cases with possible non-FTLD co-pathology,
only CSF NfL and p-tau remained statistically significant
predictors of CDR-FTLD progression rate. On average
within the bvFTD cohort, patients above the median CSF
NfL concentration (4.1 9 103 pg/mL) increased by 3.4
CDR-FTLD units annually, patients above the median p-
tau concentration (19.8 pg/mL) increased by 2.9 CDR-
FTLD units annually, and patients below the mean for
both biomarker experienced minimal clinical change
annually (Table 4). CSF p-tau/t-tau ratio was not a useful
predictor of clinical change in bvFTD.
Higher CSF NfL levels also predicted more rapid wors-
ening in other clinical measures (Table S2) including
FAQ total, MMSE total, CVLT immediate and delayed
recall, Stroop interference, and BNT total (even after
excluding cases with a CSF tau/Ab1-42 ratio over 0.52).
Additionally, higher baseline CSF p-tau also predicted
more rapid decline in the SEADL, after excluding possible
comorbid Alzheimer’s pathology.
Higher baseline CSF NfL and lower baseline Ab1-42 pre-
dicted a faster rate of frontotemporal volume loss
(Table 3, Fig. 2E and H). High baseline CSF NfL and low
baseline CSF Ab1-42 also predicted a faster rate of decline
in frontotemporal FA in patients with bvFTD (Fig. 2I and
L). The relationship between NfL and Ab1-42 with
frontotemporal imaging measures remained statistically
significant even after excluding cases with potential
co-pathology, including patients with motor neuron
disease and positive AD biomarkers (Table S2). CSF p-
tau/t-tau ratio was not a useful predictor of MR imaging
changes in bvFTD.
Baseline NfL and total tau predict change in
nfvPPA
Higher baseline CSF NfL and higher t-tau each predicted
a faster rate of CDR-FTLD SB worsening in patients with
nfvPPA (Table 3, Fig. 2A and B). On average, within the
nfvPPA cohort patients above the median t-tau NfL con-
centration (5.17 x 103pg/mL) increased by 2.4 CDR-
FTLD units annually, patients above the median t-tau
concentration (75.8 pg/mL) increased by 1.9 CDR-FTLD
units annually, and patients below the mean for either
biomarker experienced minimal clinical change annually
(Table 4).
In post hoc analyses, higher CSF NfL levels predicted a
faster rate of worsening in CGI severity, the Stroop inhi-
bition task, and sematic fluency (Table S3). Additionally,
high CSF t-tau predicted a faster rate of change in CGI
Severity.
High baseline CSF NFL and total tau were each associ-
ated with a faster rate of frontotemporal volume loss in
patients with nfvPPA (Table 3, Fig. 2E and F). High base-
line CSF NfL and t-tau also predicted a faster rate of
decline in frontotemporal FA in patients with nfvPPA
(Fig. 2I and J).
In patients with nfvPPA, the predictive value of CSF
NfL remained even after excluding possible co-pathology
(a single case with motor neuron disease). CSF p-tau and
p-tau/t-tau ratio were not a useful predictors of clinical
change in nfvPPA.
Baseline CSF biomarkers in svPPA
Within the svPPA cohort, the predictive value of CSF biomark-
ers did not meet our pre-specified criteria for statistical
Table 2. Patient demographics CSF biomarker levels by pathology.
FTLD-tau FTLD-TDP
Total, n 20 15
Autopsy proven pathology 16 8
Gene status used to
infer punitive
proteinopathy
2
(MAPT)
6
(5 C9ORF72,
1 GRN)
Clinical syndrome used
to infer proteinopathy
2
(Steele-Richardson
PSP syndrome)
1
(MND syndrome)
Mean age, years (SD) 60.7 (6.1)1 66.1 (7.0)1
Female/Male 8/12 8/7
Mean FTLD-CDRSB (SD) 10.9 (4.2)1 6.9 (3.4)1
Baseline CSF biomarker
levels
NfL pg/mL (SD) 7.7 x103
(5.9 x103)
4.9 x103
(2.6 x103)
Total Tau pg/mL (SD) 90.3 (57.1) 83.0 (28.0)
p-tau pg/mL (SD) 15.6 (11.2) 24.7 (8.5)
Ab1-42 pg/mL (SD) 360 (170) 410 (150)
Total Tau/Ab1-42 (SD) 0.30 (0.26) 0.23 (0.12)
p-tau/t-tau (SD) 0.31 (0.3)1 0.21 (0.04)1
Ab1-42, amyloid beta1-42; bvFTD, behavioral variant frontotemporal
dementia; CSF, cerebrospinal fluid; FA, fractional anisotropy; FTLD-
tau, frontotemporal lobar degeneration with tau pathology; FTLD-
TDP, frontotemporal lobar degeneration with transactive response
DNA-binding protein 43 kDa pathology; MND, motor neuron disease;
NfL, neurofilament light chain; nfvPPA, nonfluent variant primary pro-
gressive aphasia; PSP, progressive supranuclear palsy; p-tau, phospho-
rylated tau181; SD, standard deviation; svPPA, semantic variant
primary progressive aphasia; t-tau, total tau.
1Indicates a statistically significant difference between FTLD-tau than
in FTLD-tau (P < 0.05) in pairwise comparisons.
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significance after correction for multiple comparisons (Table 3,
Table S4). High baseline NfL did, however, tend to be asso-
ciated with a faster rate of decline in MMSE score, right
temporal volume, right uncinated fasciculus FA, and cor-
pus callosum genu FA. Additionally, high p-tau tended to
be associated with a faster rate of decline in lexical fluency.
CSF biomarkers have less predictive value in
svPPA and FTLD-TDP
In models containing all three clinical FTD variants, clini-
cal diagnosis and CSF biomarkers interacted to determine
the rate of disease change over time (Table S5). In gen-
eral, baseline CSF NfL predicted a greater degree of
clinical and volumetric change in bvFTD and nfvPPA
compared to svPPA. Baseline CSF t-tau also predicted a
greater degree of clinical change in nfvPPA and bvFTD
compared to svPPA. Finally, Ab1-42 predicted a greater
degree of volumetric and DTI change in bvFTD com-
pared to svPPA. These three-way interaction model
results were used to validate our approach to analyze each
FTD clinical cohort separately in our two-way interaction
models.
High baseline CSF NfL predicted a particularly large
increase in the annual rate of CDR-FTLD SB and fron-
totemporal volume loss in patients with FTLD-TDP rela-
tive to FTLD tau (Table S5). High baseline CSF p-tau
also predicted a particularly large increase in the annual
Table 3. Additional disease change with each standard deviation increase in biomarkers.
bvFTD nfvPPA svPPA
Coefficient
[CI] P
Coefficient
[CI] P
Coefficient
[CI] P
CDR-FTLD SB/year
NfL 1.4
[0.85,1.9]
<0.0005 2.1
[1.0, 3.3]
<0.0005 0.2
[0.59, 0.93]
0.665
t-tau 1.2
[0.5, 2.0]
0.0011 1.7
[0.6, 2.7]
0.002 0.7
[1.5, 0.20]
0.131
p-tau 1.3
[0.64, 2.0]
<0.0005 0.3
[0.56,1.2]
0.459 0.01
[1.0, 1.0]
0.977
Ab1-42 0.6
[1.2, 0.04]
0.07 0.7
[2, 0.57]
0.274 0.4
[1.1, 0.20]
0.169
Frontotemporal volume (mm3)/year
NfL 2.2 9 103
[3.9 9 103, 0.5 9 103]
0.009 6.2 9 103
[8.8 9 103, 3.5 9 103]
<0.0005 1.6 9 103
[3.8 9 103, 0.6 9 103]
0.161
t-tau 1.1 9 103
[3.4 9 103, 1.3 9 103]
0.363 3.5 9 103
[6.1 9 103, 0.8 9 103]
0.011 0.9 9 103
[2.6 9 103, 0.7 9 103]
0.264
p-tau 2.1 9 103
[4.6 9 103, 0.5 9 103]
0.113 1.7 9 103
[3.8 9 103, 0.32 9 103]
0.098 0.5 9 103
[2.0 9 103, 3.1 9 103]
0.691
Ab1-42 2.3 9 10
3
[0.7 9 103, 3.8 9 103]
0.004 2.4 9 103
[5.1 9 103, 0.2 9 103]
0.07 0.7 9 103
[2.1 9 103, 0.6 9 103]
0.305
Frontotemporal FA/year
NfL 5.9 9 103
[9.3 9 103, 2.5 9 103]
0.001 7.6 9 103
[12 9 103, 3.0 9 103]
0.001 5.1 9 103
[11 9 103, 1.3 9 103]
0.117
t-tau 4.6 9 103
[9.1 9 103, 2.0 9 103]
0.041 6.0 9 103
[9.6 9 103, 2.3 9 103]
0.001 3.2 9 103
[10 9 103, 3.6 9 103]
0.351
p-tau 4.9 9 103
[9.2 9 103, 0.7 9 103]
0.024 3.6 9 103
[7.4 9 103, 0.4 9 103]
0.075 5.5 9 103
[1.9 9 103, 13 9 103]
0.145
Ab1-42 4.2 9 10
3
[1.2 9 103, 7.3 9 103]
0.005 1.7 9 103
[6.1 9 103, 2.7 9 103]
0.439 2.0 9 103
[6.3 9 103, 2.3 9 103]
0.352
All coefficients shown reflect the additional annual change in denoted disease measures (added to predicted annual change at mean biomarker
level) with each standard deviation increase in the denoted baseline CSF biomarkers. All P-values shown refer to the interaction of baseline CSF
biomarker levels and time in determining the dependent variable. The depicted P-values refer to analysis including all available cases. All P-values
marked with “1” were no longer statistically significant after removing 4 bvFTD cases with a CSF t-tau/Ab1-42 ratio over 0.52. The standard devia-
tion (SD) used to calculate change was 3973 pg/mL for NfL, 37.1 pg/mL for t-tau, 9.7 pg/mL for p-tau, and 164.3 pg/mL for Ab1-42. Ab1-42, amy-
loid beta1-42; bvFTD, behavioral variant frontotemporal dementia; CI, 95% confidence interval; CSF, cerebrospinal fluid; FA, fractional anisotropy;
NfL, neurofilament light chain; nfvPPA, nonfluent variant primary progressive aphasia; p-tau, phosphorylated tau181; SD, standard deviation;
svPPA, semantic variant primary progressive aphasia; t-tau, total tau.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1257
P. A. Ljubenkov et al. CSF Biomarkers Predict FTD Trajectory
rate of CDR-FTLD SB change in FTLD-tau relative to
FTLD-TDP. High Ab1-42 was also associated with rela-
tively higher rates of frontotemporal volume loss in
FTLD-tau compared to FTLD-TDP. Given the high bur-
den of motor neuron disease within the FTD-TDP cohort,
we were unable to exclude patients with this co-pathology
in sensitivity analyses.
CSF NfL levels over time
The relationship between time and NfL change did not
meet our prespecified criteria for statistical significance in
the 27 patients with FTD and longitudinal CSF NfL data
(b = 298 pg/mL/year, 95% CI [4261, 4858], P = 0.893,
R2 = 0.02) (Fig. 3). The relationship between time and
Figure 2. Baseline CSF biomarkers predict trajectory in bvFTD and nfvPPA. All P-values shown refer to the interaction of baseline CSF biomarker
levels and time in determining the dependent variable. The depicted P-values refer to analysis including all available cases. All P-values in grey font
refer to bvFTD while P-values in black front refer to nfvPPA. All P-values marked with “†” were no longer statistically significant after removing
cases with a CSF t-tau/Ab1-42 ratio over 0.52. The Z-scores in this figure represent continuous data. The mean baseline CSF biomarker levels used
for calculating Z-scores were as follows: 5699 pg/mL NfL (SD 3973 pg/mL), 82.1 pg/mL t-tau (SD 37.1 pg/mL), 22.9 pg/mL p-tau (SD 9.7 pg/mL),
and 412.4 pg/mL Ab1-42 (SD 164.3 pg/mL). Ab1-42, amyloid beta1-42; bvFTD, behavioral variant frontotemporal dementia; CSF, cerebrospinal fluid;
FA, fractional anisotropy; NfL, neurofilament light chain; nfvPPA, nonfluent variant primary progressive aphasia; p-tau, phosphorylated tau181; SD,
standard deviation; svPPA, semantic variant primary progressive aphasia; t-tau, total tau.
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NfL change was also not statistically significant when
bvFTD (n = 14, b = 964 pg/mL/year, 95% CI [7535,
9465], P = 0.8, R2 = 0.09), svPPA (n = 5, b = 659 pg/
mL/year, 95% CI [4321, 5639], P = 0.34, R2 = 0.96),
and nfvPPA (n = 8, b = 193 pg/mL/year, 95% CI
[7058, 6672], P = 0.942, R2 = 0.06) cohorts were ana-
lyzed separately. A single case with bvFTD (a 67-year-old
ambidextrous male with no known pathogenic mutation
and a 5-year prior disease duration) was noted to experi-
ence a distinct increase in CSF NfL (+16,605 pg/mL) over
9 months. His level of clinical worsening (+3 CDR-FTLD
SB units), frontotemporal volume loss (9602 mm3), and
frontotemporal FA loss (0.01 FA) were higher than
expected for his baseline CSF biomarker levels (NfL
1149 pg pg/mL, Z score = 1.14; t-tau 38.3 pg/mL, Z
score = 1.2; p-tau 15.7 pg/mL, Z score = 0.80; Ab1-42
484.96, z score = 0.43) when compared to predicted rates
of change (Fig. 2). His baseline CSF t-tau/Ab1-42 ratio
was 0.08 (not suggestive of emerging AD co-pathology).
We did not collect data on longitudinal t-tau, p-tau, or
Ab1-42 change.
Discussion
We found that CSF NfL concentration predicts the rate of
disease progression in patients with sporadic bvFTD and
nfvPPA but not svPPA. To a lesser extent, CSF p-tau, t-
tau, and Ab1-42 were also able to predict some aspects of
disease progression in FTD. Patients with high NfL expe-
rienced the steepest annual decline in both clinical rating
scales and MRI measurements. These findings are consis-
tent with previous studies establishing the prognostic
value of both CSF7,8,36 and plasma7,9 NfL in genetic FTD
syndromes. Within our bvFTD and nfvPPA cohorts, med-
ian CSF NfL levels (4.1 9 103 pg/mL and 5.17 9 103 pg/
mL, respectively) separated patients into subgroups with
clinically significant annual change and clinically negligi-
ble annual change. While our precise median cut points
should be validated in separate cohorts, our findings sug-
gest that FTD aggressiveness can be stratified by baseline
CSF NfL. Analogous to histological grading of cancer,
NfL concentration might allow FTD aggressiveness to be
graded as low, intermediate, and high in future studies.
Our findings expand on previous research by establishing
the superior prognostic value of CSF NfL in bvFTD and
nfvPPA relative to svPPA. Additionally, our study extends
upon previous research by establishing NfL as a baseline
predictor of DTI changes in FTD. Given the role of NfL
in axonal structure and function, it is reasonable that CSF
NfL levels should predict change in imaging measures of
axon integrity.
Our study provides new information on the prognostic
value of CSF t-tau, p-tau, and Ab1-42 in differing FTD
cohorts. Our sample sizes precluded a formal analysis
using multivariate models to demonstrate a statistically
significant advantage for NfL over other CSF markers, but
NfL more consistently predicted change in disease mea-
sures among FTD variants. Compared to CSF NfL, CSF
p-tau was of similar predictive value only within our
bvFTD cohort while t-tau was of similar predictive value
only in our nfvPPA cohort. Additionally, Ab1-42 was com-
parable to NfL as a predictor or imaging changes (volu-
metric and DTI) in patients with bvFTD. The precise
determinants of CSF t-tau, p-tau, and Ab1-42 levels are
unclear. The relative levels of p-tau and t-tau may reflect
specific differences in tau production, post-translational
modification, or degradation that vary between each
FTLD pathologic subtype. Despite the unclear mechanism
of release, CSF tau is generally regarded as an indicator of
ongoing neuronal injury, so it is reasonable that CSF tau
levels should predict FTD aggressiveness. On the other
hand, the predictive value of Ab1-42 is unexpected within
a FTD cohort (particularly in light of our follow-up sensi-
tivity analysis, excluding cases that met CSF criteria for
AD co-pathology). Moreover, while low baseline Ab1-42
predicted faster radiographic change in bvFTD, we found
that high baseline CSF Ab1-42 predicted a faster volumet-
ric change in FTLD-tau compared to FTLD-TDP. If this
observation can be appropriately validated and explored
in a separate larger patient cohort, it may suggest a stark
difference in the role of Ab1-42 in FTLD-tau compared to
FTLD-TDP. There is evidence that extracellular tau regu-
lates neuronal production of amyloid beta, by mediating
neuronal hyperactivity.38 Thus, the predictive value of
Ab1-42 may reflect the downstream impact of extracellular
tau rather than the direct role of Ab1-42 in FTD patho-
physiology. Alternatively, our findings may reflect the
pathogenicity of early comorbid Ab1-42 deposition in
FTD, preceding frank biomarker-positive Alzheimer’s
Table 4. Rate of clinical change above and below median CSF bio-
marker concentrations.
Cut point used n
CDR-FTLD
annual
increase 95% CI P
bvFTD
NfL > 4.17 9 103 pg/mL 20 3.4 (2.4, 4.4) <0.0005
NfL < 4.17 9 103 pg/mL 20 0.2 (0.36, 0.83) 0.444
p-tau > 19.8 pg/mL 20 2.9 (1.9, 3.9) <0.0005
p-tau > 19.8 pg/mL 20 0.1 (0.7, 0.58) 0.849
nfvPPA
NfL> 5.17 9 103 pg/mL 13 2.4 (1.2, 3.6) <0.0005
NfL<5.17 9 103 pg/mL 13 0.1 (0.53, 0.80) 0.692
t-tau> 75.8 pg/mL 13 1.9 (0.76, 3.0) 0.001
t-tau<75.8 pg/mL 13 0.6 (0.34, 1.6) 0.203
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disease. Consistent with previous studies,36,37 patients
with FTLD-TDP had relatively low p-tau/t-tau ratios
compared to patients with FTLD-tau, and a cutoff ratio
of 0.29 gave modest sensitivity and specificity in detecting
FTLD-TDP en vivo. It should be noted that our FTLD-
TDP and FTLD-tau cohorts did not include patients with
svPPA (due to the limitations of our data), and our
FTLD-TDP cohort had a high burden of motor neuron
disease. Additionally, our patients with svPPA did not
have particularly low p-tau/t-tau ratios despite the high
incidence of FTLD-TDP in other svPPA cohorts.39 For
these reasons, the utility of CSF p-tau/t-tau ratio may be
hard to generalize outside of our own FTD cohorts.
Ultimately, the utility of CSF p-tau/t-tau ratio would be
best validated in a separate cohort with more autopsy-
confirmed pathological data.
We were unable identify clinically useful predictors of
disease trajectory in svPPA. We observed that high base-
line CSF NfL and p-tau were better at predicting disease
progression in FTLD-tau than in FTLD-TDP. Thus, it is
reasonable that CSF biomarkers should be less useful at
predicting disease change in svPPA, a cohort largely rep-
resenting FTLD-TDP pathology.39 Given our small sample
sizes, our analysis may have been underpowered to detect
relatively subtle effects of baseline NfL in svPPA. Our
conservative method of correction for multiple compar-
isons further increased the chance of type II error in our
study. Additionally, the predictive value of CSF NfL may
reach a ceiling value after which increases in NfL no
longer bestows any additional ability to predict disease
trajectory. The svPPA and FTLD-TDP cohorts tended to
have higher CSF NfL values (though this difference was
not statistically significant) and were thus more likely to
show a ceiling effect. If this were the explanation for our
discrepant findings, NfL could still be an attractive pre-
dictor in earlier phases of svPPA. In ALS cohorts, CSF
NfL is an established predictor of clinical trajectory.40
Thus, NfL is likely to have prognostic value in some
selected FTLD-TDP cohorts.
Our study did not detect a consistent increase in NfL
over time within individual disease cohorts or within the
entire FTD cohort. Our data are complemented by previ-
ous studies suggesting that CSF levels are stable over time
in ALS41 and plasma NfL levels are stable over time in
symptomatic familial FTD.7 In contrast to our cohort,
NfL levels markedly increase in FTLD mutation carriers
first transitioning to symptomatic disease.7 It is possible
that NfL may similarly change in other disease transition
points in patients who are already symptomatic. This
phenomenon may explain the distinct increase in NfL
levels over 9 months in an individual participant with
bvFTD in our study. Interestingly, one of the few studies
to consider serum NfL separately in differing primary
progressive aphasia cohorts contrasts with our study find-
ings.42 In this previous study by Steinecker et al., serum
NfL increased over time in svPPA and nfvPPA and did
Figure 3. CSF NfL concentrations are stable over time in FTD. Among the 27 cases with longitudinal CSF NfL data, there was not a statistically
significant increase in NfL over time (P = 0.893). Additionally, there was not a statistically significant change in CSF NfL when the bvFTD (n = 14,
P = 0.806), svPPA (n = 5, P = 0.345), and nfvPPA (n = 8, P = 0.953) cohorts were analyzed separately.
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not predict disease progression. Our study utilized a
smaller amount of longitudinal fluid data points and may
have consequently been less able to detect NfL change
over time in nfvPPA and svPPA. Our study, however, did
utilize LME models to leverage a larger amount of longi-
tudinal neuropsychological testing and radiographic data
points for each patient. Thus, our study may have been
better suited to identify baseline predictors of subsequent
clinical or radiographic change in separate FTD cohorts.
This study had several limitations. The longitudinal
relationship between CSF biomarkers and FTD disease
burden will be better elucidated within a larger longitudi-
nal data set. Our small sample sizes may have increased
the risk of type 1 error. Our relatively small sample size
also precluded a formal analysis using multivariate models
to demonstrate a statistically significant advantage for NfL
over other CSF markers. Our findings relied on CSF sam-
ples, which require a lumbar puncture. Given previous
data establishing the prognostic value of plasma NfL in
some clinical settings, as well as the correlation between
plasma and CSF NfL levels, future studies should empha-
size comparisons between CSF and plasma markers as
baseline predictors of decline in individual FTD cohorts.
Additionally, studies with more complete autopsy data
will help to better discern the relative utility of CSF
biomarkers in each proteinopathy group. Finally, our
study pooled NfL levels from two separate labs (albeit
using the same methods and kits). We controlled for the
site of measurement in our statistical models, but the
inclusion of two sets of data may have introduced an
additional source of error.
This study establishes CSF biomarkers as potential tools
in the design of FTD clinical trials and in prognostic deci-
sion making in patients with FTD. Our results suggest
that multiple CSF protein biomarkers predict disease pro-
gression in FTD and that CSF NfL may be a particularly
versatile measure. CSF tau and Ab1-42 may also have pre-
dictive value, though in a more limited set of clinical and
radiographic measures. Future clinical trials in FTD may
utilize CSF biomarkers in inclusion and exclusion criteria
and thus allow for greater patient uniformity and statisti-
cal power with which to establish drug efficacy. Addition-
ally, future therapeutic trials may potentially seek to levels
of NfL and other CSF biomarkers and thereby target a
predictor of improved longer-term outcomes.
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